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Abstract
Purpose Heart failure (HF) is a complex syndrome. Its
appropriate management should combine several health
measurements. We assessed the relationship between the
Kansas City Cardiomyopathy Questionnaire (KCCQ) and
the Pocock’s clinical score.
Methods We conducted a prospective registry of HF
outpatients. The main outcome was occurrence of death or
hospitalization during a 6-month follow-up. A multivariate
logistic regression was performed, including the KCCQ
overall summary score, the Pocock’s clinical score and
their interaction in the model.
Results From January 2008 to December 2010, 143
patients were involved. Mean age of patients was 68 years,
and 74 % were men. KCCQ’s overall summary score and
Pocock’s clinical score were inversely correlated
(r = -0.24, p = 0.026). A total of 61 (42.7 %) events
occurred. There was a high proportion of events (77.8 %) in
patients with a Pocock’s clinical score[50 %, whatever the
KCCQ score value. When the KCCQ score was B50 %,
there was a low increase in risk as the Pocock’s clinical score
increased (OR 2.0 [0.6; 6.6]). However, when the KCCQ
score was between 50 and 75 or C75 %, there was a high
increase in risk as the Pocock’s clinical score increased (OR
6.9 [1.2; 38.9] and OR 7.4 [0.8; 69.7], respectively).
Conclusions Patients with a high Pocock’s clinical score
are at a high risk of death or hospitalization. For patients
with a low Pocock’s clinical score, the KCCQ score can
identify those at risk of these events.
Keywords Heart failure  Kansas City Cardiomyopathy
Questionnaire  Quality of life
Introduction
Heart failure (HF) is the leading cause of hospitalization in
patients older than 65 years [1] with readmission rates over
40 % within the 6 months following a hospital discharge
[2]. The prognosis of HF is very bad, making it a major
public health problem. About half of the patients die within
the 4 years following the diagnosis of HF and more than
half in the year if the HF is severe [3]. Therefore, well-
determining HF prognosis is important and requires an
approach that cannot be limited to the use of a few
biomarkers. Other health measurements such as quality-of-
life indicators are useful. The Kansas City Cardiomyopathy
Questionnaire (KCCQ) has been developed to quantify the
health status of patients with congestive HF. It is a valid,
reliable, self-administered, 23-item questionnaire that
quantifies physical limitations, symptoms, self-efficacy,
social interference and quality of life on a 0–100 % scale
[4]. Subsequent studies have validated the KCCQ and
further demonstrated that a decrease in KCCQ is associated
with a poorer prognosis of hard outcome endpoints in HF
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patients [5, 6]. Heart failure’s prognosis in individual
patients is highly variable. Assessing the prognosis of each
patient based on his/her own overall risk score is useful for
an appropriate management. Risk models for patients with
HF exist [7, 8]. Most were developed in a single cohort of
patients, and there is therefore a need to assess their gen-
eralizability. The Meta-analysis Global Group in Chronic
HF (MAGGIC) includes individual data on 39,372 patients
with HF [9]. In this large study, Pocock and his group
established a generalizable, easy-to-use clinical score on a
0–100 % scale that increases as the risk of mortality
increases [9]. The Pocock’s clinical score is comprised of
observed factors and patient characteristics, while the
KCCQ is self-reported by patients. These two instruments
do not appear to overlap. If both of these instruments have
prognostic value in HF, then one can expect a negative
correlation between them, despite the fact that each ques-
tions differing aspects of the disease in patients. Using a
prospective registry of HF outpatients followed by general
practitioners outside of clinical settings (part of the Better
Efficacy in Lowering events by General practitioner’s
Intervention Using remote Monitoring in Heart Failure—
BELGIUM-HF study, a remote home telemonitoring study
in HF in which patients completed a six-month blind daily
weight, blood pressure and pulse measurements), we
assessed the relationship between the KCCQ and the




The BELGIUM-HF study was designed in 2007 and
implemented in 2008–2010 in Brussels and southern Bel-
gium. It was a prospective registry of HF outpatients fol-
lowed by their general practitioners (GP) but identified
from the records of 16 cardiology centers. The protocol
was approved by the ethical committee of each of the 16
centers, and an informed consent form was signed by each
of the participants. For each identified patient, his/her GP
was contacted for the study. If the GP agreed, the patient
was followed for up to 6 months by his/her GP.
Study patients
Patients were enrolled by their general practitioners in a
non-institutional environment. They were eligible if they
were hospitalized for HF in the preceding 6 months, had a
left ventricular ejection fraction (LVEF) \40 % and
required daily loop diuretics within the preceding 2 weeks
of inclusion. Excluded patients were patients\18 years of
age, patients awaiting cardiac surgery or who underwent
myocardial revascularization within the preceding
3 months, patients treated by or considered for chronic
hemodialysis procedures and patients whose cognitive
aptitudes were impaired.
Data collection
Clinical and biological data were collected at baseline.
Patients also fulfilled the KCCQ and performed the Six-
Minute Walk Test.
Health status assessment
The New York Heart Association (NYHA) classification
was used to assess patients’ cardiovascular status. The
NYHA class is a four-level scale assigning a functional
class (from I to IV) based on physical limitations caused by
cardiac symptoms. NYHA class I is defined as cardiac
disease but no symptoms and no limitation in ordinary
physical activity. NYHA class II describes mild symptoms
and slight limitation during ordinary activity. NYHA class
III is defined as an inability to perform a physical activity
without symptoms. NYHA class IV describes severe lim-
itation with symptoms even while at rest [10].
Patients enrolled in the study completed the KCCQ at
baseline. The KCCQ is a 23-item, self-administered ques-
tionnaire that encompasses several domains including
physical limitation, symptoms (frequency, severity and
recent changes), self-efficacy, social interference and
quality of life for patients with congestive HF [4]. An
overall summary score is then computed by combining
these individual scores. This summary score ranges from 0
to 100 %, and the higher the score, the better the quality of
life [4]. The questionnaire’s validity, reliability and
responsiveness to clinical change have previously been
established [11, 12]. In previous studies, the overall sum-
mary score was divided into four categories that were
associated with an increased risk of mortality and hospi-
talization for patients with decreasing scores: 0 to\24 %
(worst); 25–49 % (poor); 50–74 % (fair); and 75–100 %
(good) [13, 14].
Pocock’s clinical score
The Meta-analysis Global Group in Chronic Heart Failure
(MAGGIC) includes individual data on 39,372 patients
with HF, both reduced and preserved left ventricular
ejection fraction (EF), from 24 cohort studies and six
clinical trials [9]. It established a generalizable, easy-to-use
risk score of mortality in patients with HF using Poisson
regression models [9]. Authors identified 13 variables as
significant independent predictors of mortality in the
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following order: age, low LVEF, New York Heart Asso-
ciation (NYHA) class, serum creatinine, diabetes, absence
of a prescribed beta-blocker, low systolic blood pressure,
low body mass, time since diagnosis, current smoker,
chronic obstructive pulmonary disease, male gender and
absence of a prescribed angiotensin-converting-enzyme
inhibitor or angiotensin-receptor blockers [9]. The model-
derived clinical score was defined as the 0–100 rescaling of
the estimated regression line, with a zero score corre-
sponding to the lowest possible risk of a patient. Using this
model, we computed a risk score of each patient of the
BELGIUM-HF study.
The Six-Minute Walk Test
The Six-Minute Walk Test is a practical simple test. It
requires a 100-ft hallway but no exercise equipment or
advanced training for technicians [15]. This test measures
the distance that a patient can quickly walk on a flat, hard
surface during a period of 6 min. ‘‘It evaluates the global
and integrated responses of all the systems involved during
exercise, including the pulmonary and cardiovascular sys-
tems, systemic circulation, peripheral circulation, blood
neuromuscular units and muscle metabolism’’ [15]. Good
correlations have been reported between the Six-Minute
Walk Test and cardiopulmonary testing. In some clinical
situations, the Six-Minute Walk Test provides information
that may be a better index of the patient’s ability to perform
daily activities than is peak oxygen uptake, i.e., the 6-min
walking distance correlates better with measures of quality
of life [16]. The test was performed according to the
guidelines of the American Thoracic Society at baseline,
and the total distance walked during the test was considered.
Study outcome
The main outcome was death or hospitalization within
6 months. Both events were equally weighted to define the
outcome as a dummy variable coding for any of these two
events.
Statistical analyses
Patients’ characteristics are presented as mean with stan-
dard deviation (SD) or median with quartiles for continu-
ous variables and as number and proportion for discrete
variables. Variables with a lognormal distribution are listed
as geometric mean (SD). Pearson correlation was used to
Fig. 1 Flowchart. Out of 288
patients assessed for eligibility,
143 fulfilled the Kansas City
Cardiomyopathy Questionnaire
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assess the correlation between KCCQ subscales and the
NYHA class or the total walked distance at the Six-Minute
Walk Test. Trends across KCCQ overall summary score
categories were analyzed using Cochran–Armitage trend
test for categorical variables and Spearman’s rank correla-
tion for continuous variables. Pearson correlation was used
to assess the correlation between KCCQ scores and the
Pocock’s clinical score [9]. A multivariate logistic regres-
sion was performed, including the KCCQ overall summary
score and the Pocock’s clinical score that were encoded into
dummy variables and their interaction in the model. The
significance level was set to 0.05, and all tests were two-
sided. Statistical analyses were performed using SPSS 22.
Results
From January 2008 to December 2010, 288 patients were
eligible for study entry. However, 117 were not included
because of exclusion criteria or refusal. Among the
remaining 171 patients, another 28 patients did not com-
plete the KCCQ for various reasons (Fig. 1). A total of 143
patients filled out the KCCQ at baseline. Because this study
is a part of the BELGIUM-HF study, a remote home
telemonitoring study in HF, patients had regular contacts
with their GPs, so no hospitalization or death was lost to
follow-up.
The baseline clinical characteristics of patients are
reported in Table 1. Mean age of patients was 68 years,
with 54 % aged [70 years, and 74 % men. New York
Heart Association symptoms of class III or IV were found
in 58 %.
Figure 2 shows the distribution of the KCCQ’s sub-
scales and summary scores. At baseline, patients’ symp-
toms were stabilized and they had a positive perception of
self-efficacy. Nearly half of them had a KCCQ’s overall
summary score of at least 50 at baseline.
The difference between the cumulative KCCQ’s overall
summary score distribution of patients who experienced an
HF outcome and those who did not experience an event
Table 1 Baseline characteristics of patients






Age—years 68 ± 12 71 ± 11 66 ± 13
Male—no (%) 106 (74.1) 46 (75.4) 62 (75.6)
Body mass index (kg/m2) 27.0 ± 4.8 26.9 ± 3.7 27.0 ± 5.5
Systolic blood pressure (mmHg) 113 ± 26 112 ± 20 114 ± 29
Diastolic blood pressure (mmHg) 69 ± 17 67 ± 14 70 ± 19
NYHA class III–IV—no (%) 83 (58.0) 41 (67.2) 43 (52.4)
Risk factors
Hypercholesterolemia—no (%) 74 (51.7) 34 (55.7) 40 (48.8)
Hypertension—no (%) 82 (57.3) 31 (50.8) 51 (62.2)
Diabetes—no (%) 47 (32.9) 22 (36.1) 25 (30.5)
Smoker within past 12 months—no (%) 37 (25.9) 12 (19.7) 25 (30.5)
Six-Minute Walk Test—median (IQR) 290 (200–380) 219 (160–311) 300 (238–420)
Biological dataa
Brain natriuretic peptide (pg/ml) 741.3 (3.2) 853.9 (3.2) 621.0 (3.2)
Glucose (mg/dl) 107.2 (1.3) 109.2 (1.4) 105.7 (1.3)
Cholesterol (mg/dl) 147.9 (1.3) 137.1 (1.3) 156.9 (1.4)
LDL cholesterol (mg/dl) 79.4 (1.5) 70.5 (1.5) 84.0 (1.6)
Creatinine (mg/dl) 1.44 (1.45) 1.48 (1.48) 1.34 (1.35)
Left ventricular ejection fraction (%) 28 ± 7 28 ± 8 28 ± 7
Renal failure—no (%) 11 (7.7) 7 (11.5) 4 (4.9)
Chronic obstructive pulmonary disease—no (%) 22 (15.4) 11 (18.0) 11 (13.4)
Plus minus data are mean ± SD
NYHA New York Heart Association, LDL low-density lipoprotein
a Data are geometric means (SD)
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Fig. 2 Distribution of Kansas
City Cardiomyopathy
Questionnaire subscales and
summary scores in patients with
heart failure. At baseline, most
of the patients had symptoms
remission and felt self-efficacy.
Nearly half of the patients had
an overall summary score of at
least 50 %
Table 2 Baseline variables identified by Pocock with trends across the Kansas City Cardiomyopathy Questionnaire’s (KCCQ)
All patients
n = 143













Trend test p value
Age—years 68 ± 12 67 ± 13 71 ± 12 67 ± 13 67 ± 11 0.57
Left ventricular ejection fraction (%) 28 ± 7 28 ± 7 27 ± 6 27 ± 8 29 ± 8 0.40
NYHA class III–IV—no (%) 83 (58.0) 24 (75.0) 35 (77.8) 18 (46.2) 6 (22.2) \0.001
Creatininea (mg/dl) 1.44 (1.45) 1.30 (1.44) 1.50 (1.4) 1.45 (1.44) 1.30 (1.44) 0.49
Diabetes—no (%) 46 (32.2) 11 (34.4) 9 (20.0) 17 (43.6) 9 (33.3) 0.45
Beta-blocker—no (%) 114 (79.7) 30 (93.8) 34 (75.6) 29 (74.4) 21 (77.8) 0.13
Systolic blood pressure (mmHg) 113 ± 26 116 ± 20 115 ± 23 110 ± 32 107 ± 27 0.12
Body mass index (kg/m2) 27.0 ± 4.8 28.4 ± 5.9 26.2 ± 5.4 26.7 ± 4.3 27.0 ± 3.4 0.92
Time since diagnosis (months) 38 ± 44 41 ± 45 41 ± 37 44 ± 55 23 ± 35 0.09
Smoker within past 12 months—no
(%)
36 (25.2) 11 (34.4) 9 (20.0) 7 (17.9) 9 (33.3) 0.80
COPD—no (%) 22 (15.4) 9 (28.1) 8 (17.8) 4 (10.3) 1 (3.7) 0.008
Male—no (%) 106 (74.1) 23 (71.9) 32 (71.1) 28 (71.8) 23 (85.2) 0.29
ACEor Sartan—no (%) 135 (94.4) 27 (84.4) 44 (97.8) 38 (97.4) 26 (96.3) 0.07
Pocock’s clinical score 34 ± 15 38 ± 16 36 ± 14 34 ± 16 31 ± 14 0.04
Plus minus data are mean ± SD
COPD chronic obstructive pulmonary disease, ACE angiotensin-converting-enzyme inhibitor
a Data are geometric means (SD)
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was not Gaussian along the continuous level of the KCCQ
score. Indeed, the two curves were not sigmoids, and the
difference was larger for KCCQ scores around 25 %.
Consequently, the KCCQ score could not be considered as
a continuous scale, and it was more relevant to considering
a four-point scale (quartiles) than a hundred-point scale
(Online Resource 1).
Table 2 summarizes the 13 Pocock’s independent pre-
dictors of mortality in patients with HF and their rela-
tionship with the previously described categories of the
KCCQ’s overall summary score [9]. Only 18.9 % of
patients reported a good KCCQ’s overall summary score at
baseline (C75 %). A worst KCCQ’s overall summary score
(B25 %) was found in 22.4 % of patients. The proportion
of patients with the most severe symptoms on NYHA
classification increased as the KCCQ’s overall summary
score decreased (trend p\ 0.001). The same observation
was made for the proportion of patients with a chronic
obstructive pulmonary disease (trend p = 0.008). Such
variables are measures of physical capacities that are
expected to be correlated with tools measuring perceived
health such as the KCCQ. In contrast, other variables such
as creatininemia and the use or not of beta-blockers are not
expected to reflect a perceived health. When taking into
account all of the 13 variables to compute Pocock’s clinical
score, it was observed that the mean Pocock’s clinical
score increased as the KCCQ’s overall summary score
decreased (trend p = 0.04). KCCQ’s overall summary
score was inversely correlated with the Pocock’s clinical
risk score (r = -0.24, p = 0.026).
Table 3 Patients’ other characteristics









Trend test p value
Clinical data
Diastolic blood pressure (mmHg) 69 ± 17 72 ± 14 68 ± 14 68 ± 21 67 ± 18 0.32
Pulse rate—beats per minute 78 ± 18 81 ± 16 78 ± 16 78 ± 21 76 ± 19 0.09
Sinusal rhythm—no (%) 109 (76.2) 23 (71.9) 35 (77.8) 29 (74.4) 22 (81.5) 0.04
Pulmonary rhoncus—no (%) 47 (32.9) 14 (43.8) 18 (40.0) 8 (20.5) 7 (25.9) \0.001
Jugular distension—no (%) 36 (25.2) 13 (40.6) 16 (35.6) 6 (15.4) 1 (3.7) 0.003
Peripheral edema—no (%) 52 (36.4) 15 (46.9) 24 (53.3) 7 (17.9) 6 (22.2)
Six-Minute Walk Test distance (m) 298 ± 130 258 ± 138 280 ± 149 311 ± 127 334 ± 105 0.04
Biological dataa
Brain natriuretic peptide (pg/ml) 741.3 (3.2) 977.2 (2.9) 630.9 (3.6) 660.7 (2.6) 676.1 (3.4) 0.29
Glucose (mg/dl) 107.2 (1.3) 107.2 (1.3) 100.0 (1.2) 109.6 (1.4) 114.8 (1.5) 0.51
Troponin (lg/l) 0.034 (2.6) 0.032(0.347) 0.030 (2.820) 0.033 (1.995) 0.047 (2.754) 0.47
Plus minus data are mean ± SD
a Data are geometric means (SD)
Table 4 Correlations between
KCCQ subscales and NYHA
class or Six-Minute Walk Test
NYHA p value Walk distance p value
Kansas City Cardiomyopathy Questionnaire subscales
Physical limitation -0.46 \0.001 0.18 0.04
Symptom stability -0.08 0.02 0.33 0.01
Symptom frequency -0.43 \0.001 0.31 0.01
Symptom burden -0.40 \0.001 0.26 0.04
Total symptom score -0.43 \0.001 0.30 0.02
Self-efficacy -0.14 0.09 0.18 0.16
Quality of life -0.33 \0.001 0.27 0.03
Social limitation -0.39 \0.001 0.24 0.07
Overall summary score -0.44 \0.001 0.27 0.03
Clinical summary score -0.46 \0.001 0.25 0.04
1250 Qual Life Res (2016) 25:1245–1255
123
Other patient characteristics such as the proportion of
patients in sinus rhythm (trend p = 0.04) and the mean
walk distance at the Six-Minute Walk Test (trend
p = 0.04) decreased with the KCCQ’s overall summary
score (Table 3). Mean diastolic blood pressure (trend
p = 0.32), mean pulse rate (trend p = 0.09), the proportion
of patients with pulmonary rhoncus (trend p\ 0.001) and
those with peripheral edema (trend p = 0.003) increased as
the KCCQ’s overall summary score decreased (Table 3).
We also observed that brain natriuretic peptide levels were
the highest in patients with a low KCCQ’s overall sum-
mary score (Table 3).
When looking at the correlation between each of the
KCCQ subscales and the NYHA class, we found all sig-
nificant negative correlations except for the self-efficacy
subscale (p = 0.09), showing low KCCQ values in patients
from high NYHA classes. In addition, the walk distance for
the Six-Minute Walk Test was positively correlated with
all KCCQ subscales except the self-efficacy subscale
(p = 0.16), similarly showing low walk distances in
patients with lower KCCQ values, who are also the frailest
patients (Table 4).
During the 6 months of follow-up, 10 (7.0 %) patients
died. In addition, 51 (35.7 %) were reported hospitalized,
resulting in 42.7 % of patients presenting an event during
the 6 months following study start. Patients who experi-
enced an event were older and had more severe symptoms
on NYHA classification (Table 1). They also had higher
levels of brain natriuretic peptide and a smaller mean walk
distance at the Six-Minute Walk Test (Table 1).
Patients who experienced an event had a higher
Pocock’s clinical score at baseline as illustrated in Fig. 3.
Almost all patients with a high Pocock’s clinical score
(C50 %) experienced an event regardless of the KCCQ’s
overall summary score. For patients with a medium
(25–50 %) or a low (B25 %) Pocock’s clinical score, we
observed a morbi-mortality gradient according to the
KCCQ’s overall summary score. Indeed, the number of
events observed in these patients increased as their
KCCQ’s overall summary score worsened (Fig. 4).
Using multivariate logistic regression, the estimated
equation for the KCCQ overall summary score and the
Pocock’s clinical score was the following:
LogitðpÞ ¼ 2:303 þ 1:996  Pocock2550% þ 1:514
 KCCQ 50% þ 0:693  KCCQ5075%
 1:304  Pocock2550%  KCCQ 50%
 0:059  Pocock2550%  KCCQ5075%
A significant interaction was found between the KCCQ
overall summary score and the Pocock’s clinical score.
This interaction is illustrated in Table 5. There was a high
proportion of events (14/18 = 77.8 %) in patients with a
high ([50 %) Pocock’s clinical score, whatever the KCCQ
Fig. 3 Histogram of Pocock’s
clinical score according to event
occurrence. Patients who
experienced an event had the
highest Pocock’s clinical scores
at baseline
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score value. When the KCCQ score was B50 % (top
panel), there was a low increase in risk as the Pocock’s
clinical score increased (OR 2.00, 95 % CI 0.60–6.62). But
when the KCCQ score was between 50 and 75 % (middle
panel) or C75 % (lower panel), there was a high increase in
risk as the Pocock’s clinical score increased (OR 6.94,
95 % CI 1.24–38.86, and OR 7.36, 95 % CI 0.78–69.70,
respectively).
Comparing the KCCQ subscales mean scores with
respect to the occurrence of death or hospital admission in
the subgroup of patients with a medium or a low Pocock’s
clinical score, we observed that patients who experienced
an event had lower mean scores for each of these ten
subscales. The difference between mean scores was about 3
for all subscales except for self-efficacy, where it reached
10 (Online Resource 2).
Fig. 4 Kansas City
Cardiomyopathy
Questionnaire’s overall
summary score and Pocock’s
clinical score according to event
occurrence. Patients with a
significantly affected Pocock’s
clinical score ([50 %) have
almost all experienced an event.
For patients with a slightly
affected Pocock’s clinical sore
(B50 %) at baseline, we
observed a morbi-mortality
gradient according to the KCCQ
overall summary score. Indeed,
the proportion of events in these
patients increased as their
KCCQ overall summary score
worsened
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Discussion
The purpose of this study was to assess the relationship and
the additive prognostic value of the KCCQ, a validated
measurement tool for patient-perceived health status in
congestive HF, and the Pocock’s clinical score of mortality
in HF patients. We found an inverse correlation between
the KCCQ’s overall summary score and the Pocock’s
clinical score. This indicates that patients with a signifi-
cantly affected Pocock’s clinical score also tend to have a
poorer quality of life. When Pocock’s clinical score is high
([50 %), there is no additional prognostic value of
KCCQ’s overall summary score for hospital admission or
death within 6 months. However, when Pocock’s clinical
score is medium (25–50 %) or low (B25 %), KCCQ’s
overall summary score has a significant prognostic value.
Therefore, these two instruments are complementary ways
to assess the progression of HF.
Pocock’s clinical score has an interesting prognostic
value in that patients with a high Pocock’s clinical score
almost all experienced an event.
As already established [4], we reported a negative cor-
relation between KCCQ and NYHA class and a positive
correlation between KCCQ and walk distance at the Six-
Minute Walk Test. Nonetheless, we observed that the
KCCQ’s self-efficacy subscale was not significantly cor-
related with the NYHA class or to the walk distance at the
Six-Minute Walk Test, in contrast to the other nine sub-
scales of the KCCQ. This reflects the fact that most KCCQ
subscales and the NYHA classification assess the patient’s
physical limitations. For the KCCQ subscales, this limita-
tion is based on the patient’s perspective, and for the
NYHA classification, it is based on the physician’s
perspective [17, 18]. In contrast, the self-efficacy subscale
assesses a very subjective aspect related to the knowledge
of the patient about his/her HF. This is consistent with the
findings of a recent study conducted to reconceptualize
KCCQ subscales and to advance its use, more than
10 years after its publication [19].
We further observed that patients who experienced an
event had the lowest mean scores for all KCCQ’s sub-
scales. The difference between these mean scores was the
highest for the self-efficacy subscale. Thus, the KCCQ’s
self-efficacy subscale does not seem consistent with the
other KCCQ’s subscales, but it evaluates an important
health status, i.e., patient autonomy, and requires thorough
assessment.
Our study has limitations, and the small sample size is
the main one. Nevertheless, despite our small number of
patients, there are several arguments proving the quality of
our data base. Firstly, as we have just discussed, patients
were recruited by their general practitioners in a non-in-
stitutional environment. Such a sample is smaller, but it is
more representative of patients with HF in their daily life,
outside of hospitals. In this respect, it is original and
deserves special attention. Secondly, with a small sample,
we observed 42.7 % of events at 6 months, which is con-
sistent with the 40 % [2] reported in the literature. Thirdly,
we found consistent correlations between all the KCCQ
subscales and the NYHA class and walk distance at Six-
Minute Walk test, as already established. Finally, we found
the prognostic value of the Pocock’s clinical score. All
these give a power to generalize our findings.
In conclusion, patients with a high Pocock’s clinical
score are at a high risk of death or hospitalization during a
6-month follow-up and the KCCQ does not add prognostic
Table 5 Multivariate logistic
regression: predictive value of








KCCQ overall summary score: high risk (B50 %)
Pocock’s clinical score: high risk (C50 %) 11 7 (63.6) Not computedb
Pocock’s clinical score: medium risk (25–50 %) 48 23 (47.9) 2.00 [0.60; 6.62]
Pocock’s clinical score: low risk (B25 %) 16 5 (31.3) 1
KCCQ overall summary score: medium risk (50–75 %)
Pocock’s clinical score: high risk (C50 %) 5 5 (100.0) Not computedb
Pocock’s clinical score: medium risk (25–50 %) 23 13 (56.5) 6.94 [1.24; 38.86]
Pocock’s clinical score: low risk (B25 %) 12 2 (16.7) 1
KCCQ overall summary score: low risk (C75 %)
Pocock’s clinical score: high risk (C50 %) 2 2 (100.0) Not computedb
Pocock’s clinical score: medium risk (25–50 %) 17 7 (41.2) 7.36 [0.78; 69.70]
Pocock’s clinical score: low risk (B25 %) 9 1 (11.1) 1
OR odds ratio
a 95 % confidence interval
b Because of 64–100 % events
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value. For patients with a low Pocock’s clinical score, the
KCCQ score allows for further characterization of a still
high risk group. That information might lead to targeting
therapies interventions to mitigate that group’s risk of
death or hospitalization. These two instruments are there-
fore complementary in assessing health in its globality for
HF patients. KCCQ may therefore represent a different
approach in HF management.
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